Topotecan Injection
Product Images NDC 16729-243

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Topotecan (NDC 16729-243). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Accord Healthcare Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 2 (Topotecan 1 mg Per mL Carton)

Topotecan Injection 1 mg/mL vial label by Accord Healthcare Inc. The label states it is a cytotoxic agent requiring dilution before intravenous infusion and is for prescription use only. It is packaged as a 1 mL multiple-dose vial. Storage instructions and cautionary details about toxicity and handling are included.*

FDA Label Image

Image 1 (Topotecan 1 mg Per mL Container Label)

Topotecan Injection 1 mg/mL in a 1 mL multidose vial from Accord Healthcare Inc. The label indicates it is for intravenous infusion and is a cytotoxic agent. Storage instructions advise keeping at 20°C to 25°C with protection from light. The label includes a barcode, handling precautions, and manufacturing information stating the product is made in India for Accord Healthcare, Durham, NC.*

FDA Label Image

Image 4 (Topotecan 4 mg Per 4 mL Carton)

Topotecan Injection 4 mg/4 mL (1 mg/mL) vial label from Accord Healthcare Inc. The label states it is for intravenous infusion and must be diluted before use. It is a prescription drug supplied in a 4 mL multiple-dose vial. The label includes warnings about cytotoxicity, storage instructions, and a caution that it is a cytotoxic agent.*

FDA Label Image

Image 3 (Topotecan 4 mg Per 4 mL Container Label)

Topotecan Injection 4 mg/4 mL (1 mg/mL) multiple-dose vial label by Accord Healthcare Inc. The label includes handling instructions noting it is a cytotoxic agent and requires dilution before intravenous use. Storage instructions specify temperatures between 20°C to 25°C, protection from light, and use within 28 days after first use. The label also includes the NDC 16729-243-31 and manufacturer information.*

FDA Label Image

Figure 10 (Topotecan Graph1)

A survival curve graph comparing Topotecan Injection plus Cisplatin versus Cisplatin Monotherapy. The y-axis shows the proportion surviving, and the x-axis shows months on study. The graph illustrates survival trends over approximately 36 months, with a table below indicating the number of patients at risk at various time points for both treatment groups.*

FDA Label Image

Structural Formula (Topotecan Structure)

Chemical structure diagram of Topotecan hydrochloride. The image shows the molecular rings and functional groups characteristic of the Topotecan molecule with the hydrochloride component indicated separately as [HCl]n.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.